We have located links that may give you full text access.
Congress
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Chemical-induced vasculature injury. Summary of the symposium presented at the 32nd annual meeting of the Society of Toxicology, New Orleans, Louisiana, March 1993.
Toxicology and Applied Pharmacology 1995 June
The cross-sectional structure of the vasculature is comparatively simple, comprising three layers--the intima, adjacent to the lumen, the media, and the adventitia. Notwithstanding this simplicity, the vessels are host to a variety of reactions to injury. Two cell types, endothelial cells of the intima and smooth muscle cells of the media, are principal targets of damage and repair. The endothelial cells of the intimal layer of the vessel wall present a macromolecular barrier and are important in maintaining vessel integrity. When the integrity is compromised by physical or chemical injury, endothelial cells play a key role in the repair processes. The use of single-cell wound models allows the mechanisms of damage and subsequent repair to be studied in depth. Repair processes can be observed using time-lapse photography and differences between cytoskeleton changes during repair and reendothelialization of small and large wounds can be discriminated. In rats treated with the plant toxin monocrotaline, pulmonary vascular injury occurs which manifests as thrombosis and remodeling with consequent progressive pulmonary hypertension. In vivo and in vitro studies of the mechanism of monocrotaline toxicity suggest that the endothelial cells are an important target. In vitro studies show monocrotaline to be directly cytotoxic; in cells that survive, there are functional changes to the endothelial cells, resulting in a decreased repair capability which may lead to the complex, progressive lung lesions that develop. The other target cells of the vasculature are the smooth muscle cells of the media. Ingestion of primary amines allylamine and beta-aminopropionitrile (beta-APN) results in chronic vasculotoxicity to the aorta and medium-sized arteries. For allylamine, subtle changes in smooth muscle result in medial hypertrophy and subintimal proliferation. The changes are slow to occur, taking weeks or months of repeated treatment. For beta-APN, which is the active ingredient of the toxic sweet pea Lathyrus odoratous, vascular toxicity is manifested by fatal rupture of aortic aneurysms. When these agents are administered concomitantly, a synergistic acute smooth muscle necrosis occurs in large elastic arteries and degenerative changes are seen in muscular arteries. A change in the target for toxicity of allylamine toward the vasculature may be responsible for this synergistic toxic insult. Medial smooth muscle necrosis is also noteworthy after administration of certain pharmaceutical agents of diverse structure and pharmacological activity. These agents induce arteriopathies in dogs and rats, although at different sites. In dogs, the coronary arteries are susceptible, whereas in rats the mesenteric arteries are the principal sites of injury.(ABSTRACT TRUNCATED AT 400 WORDS)
Full text links
Related Resources
Trending Papers
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app